The device will be used to rehabilitate patients with this neurological condition.
June 14, 2022 | | Reading time: 2 min
Device developed by Ekso Bionics Holdings for the treatment of patients with multiple sclerosis. Photo: Ekso Bionics Holdings.
US Food and Drug Administration (FDA) ExoNR approved robotic exoskeleton to carryfrom Ekso Bionics Holdings, in 2016 for use in rehabilitation after stroke d spinal cord injuries and in 2020 for use in acquired brain injuries (ABI).
According to the company, the EksoNR is based on its predecessor, the Ekso GT, and is a “next generation” motorized exoskeleton of the lower body with gait assistance. for physical and neurological rehabilitation.
“As a leader in portable robotic merchandising solutions treatment for medical rehabilitation, we are committed to maximizing patients’ access to our technology, “said Stephen Sherman, President and CEO of Ekso Bionics, in a press release.
“With indications for use that have now been expanded to include MS, EksoNR has the potential to help significantly more patients and improving patient mobilitysaid Sherman.
“We are excited to see that the device is beneficial for patients with MS, providing critical rehabilitation solutionsjust as has happened to stroke patients, a spinal cord injury and acquired brain trauma, “he added.
According to the company, Ekso devices are used in more than 375 rehabilitation centers around the world and have helped patients to give almost 200 million steps, while supporting patients’ hopes for mobility and independence.
Source consulted here.